Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

“However, the downstream equipment presents a much bigger challenge due to the significant investment required to add capacity to the proofer and oven, if possible at all,” he pointed out. “Another ...

One of the most important bioprocessing advances in recent years has been the rise in levels of manufactured therapeutic proteins. Indeed, the overall average yield reported for commercial monoclonal ...

The cell and gene therapy industry will greatly benefit from access to robust, scalable, end-to-end solutions for the production and characterization of native and engineered exosome therapeutics.” — ...

LONDON--(BUSINESS WIRE)--Quantzig is one of the world’s leading analytics solutions providers, committed to offering cutting-edge analytics solutions to help organizations institutionalize data-driven ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.